29:
362:
189:
243:. In a phase 2a trial, the higher dosage levels reduced liver fat on average by more than 30 percent and also reduced body weight significantly. A phase 2b trial was launched in late 2023.
289:"Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial"
287:
Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J (December 2023).
240:
203:
367:
239:
and improve safety." Developed by Rivus
Pharmaceuticals, the drug is tested to reduce weight and liver fat in humans with risk factors for
260:
Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). "Clinical Trial
Landscape in NASH".
65:
41:
320:
235:(DNP) that is intended to "minimize the rapid absorption and high peak blood concentrations of DNP to provide a wider
377:
372:
357:
321:"Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments"
82:
352:
236:
232:
91:
300:
269:
132:
305:
288:
116:
346:
273:
165:
229:
28:
225:
102:
20:
363:
Experimental drugs developed for non-alcoholic fatty liver disease
188:
179:
177:
164:
131:
126:
101:
81:
56:
40:
35:
241:metabolic dysfunction-associated steatohepatitis
115:
90:
8:
293:The Lancet Gastroenterology & Hepatology
19:
27:
304:
211:CN1C(=CN=C1(=O))COC2=C(C=C(C=C2)(=O))(=O)
262:Clinical Gastroenterology and Hepatology
252:
208:
70:
18:
7:
106:
14:
149:
143:
368:Experimental anti-obesity drugs
155:
137:
1:
306:10.1016/S2468-1253(23)00198-X
73:5--1-methyl-2-nitroimidazole
394:
127:Chemical and physical data
274:10.1016/j.cgh.2023.03.041
199:
61:
26:
228:of the mitochondrial
23:
327:. 15 November 2023
299:(12): 1094–1105.
237:therapeutic index
233:2,4-dinitrophenol
219:
218:
190:Interactive image
16:Chemical compound
385:
337:
336:
334:
332:
317:
311:
310:
308:
284:
278:
277:
268:(8): 2001–2014.
257:
192:
172:
157:
151:
145:
139:
119:
109:
108:
94:
31:
24:
22:
393:
392:
388:
387:
386:
384:
383:
382:
378:Nitroimidazoles
343:
342:
341:
340:
330:
328:
319:
318:
314:
286:
285:
281:
259:
258:
254:
249:
215:
212:
207:
206:
195:
170:
160:
154:
148:
142:
122:
105:
97:
77:
74:
69:
68:
52:
49:Investigational
17:
12:
11:
5:
391:
389:
381:
380:
375:
370:
365:
360:
355:
345:
344:
339:
338:
312:
279:
251:
250:
248:
245:
217:
216:
214:
213:
210:
202:
201:
200:
197:
196:
194:
193:
185:
183:
175:
174:
168:
162:
161:
158:
152:
146:
140:
135:
129:
128:
124:
123:
121:
120:
112:
110:
99:
98:
96:
95:
87:
85:
79:
78:
76:
75:
72:
64:
63:
62:
59:
58:
54:
53:
51:
50:
46:
44:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
390:
379:
376:
374:
373:Nitrobenzenes
371:
369:
366:
364:
361:
359:
356:
354:
351:
350:
348:
326:
325:Yahoo Finance
322:
316:
313:
307:
302:
298:
294:
290:
283:
280:
275:
271:
267:
263:
256:
253:
246:
244:
242:
238:
234:
231:
227:
223:
209:
205:
198:
191:
187:
186:
184:
181:
176:
169:
167:
163:
136:
134:
130:
125:
118:
114:
113:
111:
104:
100:
93:
89:
88:
86:
84:
80:
71:
67:
60:
55:
48:
47:
45:
43:
39:
34:
30:
25:
329:. Retrieved
324:
315:
296:
292:
282:
265:
261:
255:
221:
220:
92:2231311-68-3
42:Legal status
36:Legal status
173: g·mol
57:Identifiers
358:Uncouplers
347:Categories
331:3 December
247:References
178:3D model (
166:Molar mass
83:CAS Number
66:IUPAC name
230:uncoupler
117:135205989
353:Prodrugs
226:prodrug
171:323.221
133:Formula
103:PubChem
204:SMILES
224:is a
180:JSmol
333:2023
301:doi
270:doi
222:HU6
107:CID
21:HU6
349::
323:.
295:.
291:.
266:21
264:.
141:11
335:.
309:.
303::
297:8
276:.
272::
182:)
159:7
156:O
153:5
150:N
147:9
144:H
138:C
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
